Iulia Andras1,2, Nicolae Crisan1,2, Stefan Vesa3, Razvan Rahota2, Florina Romanciuc4, Andrei Lazar4, Carmen Socaciu4, Deliu-Victor Matei5, Ottavio de Cobelli5, Ioan-Stelian Bocsan6, Radu-Tudor Coman6. 1. Department of Urology, Iuliu Hatieganu University of Medicine & Pharmacy, Cluj-Napoca, Romania. 2. Department of Urology, Clinical Municipal Hospital, Cluj-Napoca, Romania. 3. Department of Pharmacology, Toxicology & Clinical Pharmacology, Iuliu Hatieganu University of Medicine & Pharmacy, Cluj-Napoca, Romania. 4. Center for Applied Biotechnology BIODIATECH, SC Proplanta, Cluj-Napoca, Romania. 5. Department of Urology, European Institute of Oncology, Milan, Italy. 6. Department of Epidemiology, Iuliu Hatieganu University of Medicine & Pharmacy, Cluj-Napoca, Romania.
Abstract
AIM: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy. PATIENTS & METHODS: Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed. RESULTS: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy. CONCLUSION: Metabolomic analysis can predict the outcome of the first systematic biopsy.
AIM: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy. PATIENTS & METHODS: Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed. RESULTS: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy. CONCLUSION: Metabolomic analysis can predict the outcome of the first systematic biopsy.
Entities:
Keywords:
biopsy; metabolomics; prediction score; prostate cancer
Authors: Iulia Andras; Emanuel Darius Cata; Andreea Serban; Pierre Kadula; Teodora Telecan; Maximilian Buzoianu; Maria Bungardean; Dan Vasile Stanca; Ioan Coman; Nicolae Crisan Journal: Medicina (Kaunas) Date: 2021-05-22 Impact factor: 2.430